Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Operating Income Loss of -$125.70 million for the year ending 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +8.0% in Operating Income Loss from 2024 to 2025.
- This data is from Tonix Pharmaceuticals Holding Corp.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: -$1.16 million | Q2 2012: -$1.73 million | Q3 2012: -$1.73 million | Q1 2013: -$2.00 million | Q2 2013: -$2.09 million | Q3 2013: -$3.09 million | Q1 2014: -$5.17 million | Q2 2014: -$6.05 million | Q3 2014: -$7.43 million | Q4 2014: -$9.00 million | Q1 2015: -$9.70 million | Q2 2015: -$11.78 million | Q3 2015: -$13.28 million | Q4 2015: -$13.40 million | Q1 2016: -$14.01 million | Q2 2016: -$9.84 million | Q3 2016: -$7.61 million | Q1 2017: -$5.09 million | Q2 2017: -$4.82 million | Q3 2017: -$5.84 million | Q1 2018: -$6.99 million | Q2 2018: -$6.14 million | Q3 2018: -$5.54 million | Q1 2019: -$6.30 million | Q2 2019: -$5.91 million | Q3 2019: -$7.89 million | Q1 2020: -$7.30 million | Q2 2020: -$14.19 million | Q3 2020: -$12.00 million | Q1 2021: -$20.74 million | Q2 2021: -$23.56 million | Q3 2021: -$18.54 million | Q1 2022: -$26.44 million | Q2 2022: -$23.34 million | Q3 2022: -$29.59 million | Q1 2023: -$33.90 million | Q2 2023: -$29.00 million | Q3 2023: -$28.15 million | Q1 2024: -$21.35 million | Q2 2024: -$77.32 million | Q3 2024: -$15.55 million | Q1 2025: -$16.05 million | Q2 2025: -$28.30 million | Q3 2025: -$33.07 million.
- Over the full 16 years of available data (2010 to 2025), Tonix Pharmaceuticals Holding Corp.'s Operating Income Loss has declined by 6,417.5%.
- Historical annual values: Fiscal year 2025: -$125.70 million | Fiscal year 2024: -$136.70 million | Fiscal year 2023: -$118.38 million | Fiscal year 2022: -$112.09 million | Fiscal year 2021: -$92.31 million | Fiscal year 2020: -$50.51 million | Fiscal year 2019: -$28.83 million | Fiscal year 2018: -$26.32 million | Fiscal year 2017: -$21.29 million | Fiscal year 2016: -$38.97 million | Fiscal year 2015: -$48.16 million | Fiscal year 2014: -$27.66 million | Fiscal year 2013: -$10.89 million | Fiscal year 2012: -$6.66 million | Fiscal year 2011: -$3.38 million | Fiscal year 2010: -$1.93 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: